Literature DB >> 27531115

[Diagnosis and treatment of ocular hypertension].

Y Y Sun1, W W Chen, N L Wang.   

Abstract

Ocular hypertension is popular among people, with a prevalence of 3% to 10% in those older than 40 years old. Without proper intervention, over 10% of the patients with ocular hypertension would develop glaucoma in the following 5 to 10 years. Glaucoma has become one of the leading causes of blindness all over the world, which makes it essential for us to pay enough attention to the prevention and treatment of ocular hypertension. However, it is not cost-effective to treat all the patients with ocular hypertension. Certain side effects may also be caused with long-term medical treatment. Therefore, it is of great importance for ophthalmologists to identify the right time and use appropriate therapeutic methods. To introduce the knowledge of ocular hypertension, the definition, epidemiology, diagnosis, risk factors and treatment of ocular hypertension are reviewed in this article. (Chin J Ophthalmol, 2016, 52: 542-546).

Entities:  

Mesh:

Year:  2016        PMID: 27531115     DOI: 10.3760/cma.j.issn.0412-4081.2016.07.016

Source DB:  PubMed          Journal:  Zhonghua Yan Ke Za Zhi        ISSN: 0412-4081


  3 in total

1.  Treatment of glaucoma among elderly patients in Sofia.

Authors:  Milcheva Evelina Marinova; Krasimirova Emilia Naseva; Todorov Yani Zdravkov; Stoimenov Dimitar Dabov
Journal:  Rom J Ophthalmol       Date:  2020 Oct-Dec

2.  The Effectiveness of Laser Peripheral Iridotomy in Adolescent Eyes with Ocular Hypertension and Concave Configuration of the Peripheral Iris.

Authors:  Alina Bakunowicz-Łazarczyk; Beata Urban; Małgorzata Krętowska
Journal:  J Ophthalmol       Date:  2022-02-28       Impact factor: 1.909

3.  A Comparative Study of the Clinical Efficacy and Safety of Pneumatic Trabeculoplasty and Selective Laser Trabeculoplasty for Patients with Primary Open-Angle Glaucoma or Ocular Hypertension.

Authors:  Yanling Song; Qiujie Song; Yanhui Qin; Jinfeng Xu; Ping Chen; Hong Li; Wenjie Han
Journal:  Med Sci Monit       Date:  2021-12-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.